Leidos (LDOS) Q2 2026 earnings review
Robust Cash Flow and Guidance Hike Mask a Bottom-Line Contraction
Leidos delivered a mixed Q2 that management aggressively framed as a win by raising full-year guidance across the board. While revenue grew 7% YoY to $4.56B—driven by a 32% surge in the Homeland segment and the Entrust acquisition—profitability told a different story. GAAP Net Income reversed, falling 9% YoY to $356M, burdened by $29M in acquisition and restructuring costs. Adjusted EBITDA margin also decelerated to 13.8% from 15.2% a year ago, primarily due to tough comparables and a lagging Health segment. However, the company's cash-generation engine remains exceptional, yielding $793M in operating cash flow and funding rapid debt paydown.
🐂 Bull Case
The Homeland segment is accelerating rapidly, with revenue up 32% YoY to $1.02B. The integration of Entrust ($141M contribution) and strong Air Traffic and Energy demand are transforming this segment into Leidos' primary growth engine.
Operating cash flow hit a massive $793M for the quarter (224% conversion ratio). This allows Leidos to aggressively pay down M&A debt ($300M in Q2) while continuing shareholder returns, keeping leverage ratios extremely healthy.
🐻 Bear Case
The Health business—historically a high-margin profit center—saw revenue decline 8% and operating margins compress 240 bps to 23.4% as medical disability exam volumes dropped.
While Non-GAAP EPS grew 2%, GAAP Net Income fell 9%. The aggressive 'NorthStar 2030' portfolio shaping is incurring significant near-term friction costs ($29M this quarter) that are eating into the bottom line.
⚖️ Verdict: ⚪
Neutral/Bullish. The underlying defense and infrastructure demand is incredibly strong, and the cash flow supports the strategic M&A pivot. But investors should closely monitor the deterioration in the Health segment and the gap between GAAP and Non-GAAP earnings.
Key Themes
Homeland Security Accelerating via Entrust
The Homeland segment was the standout performer, with revenue up 32% YoY to $1.02 billion. This was heavily driven by the ENTRUST Solutions acquisition, which contributed $141M in the quarter. Crucially, this revenue growth was accretive to profitability: Non-GAAP operating margin expanded from 9.3% to 12.1%, driven by a better mix of security products and strong energy grid modernization demand.
Health Segment Profitability Reversing
Leidos' Health segment is showing clear signs of deceleration. Revenues dropped 8% to $1.09B, driven by lower medical disability exam volumes—a direct shift from the record volumes seen in FY25. As volume declined, so did operating leverage: segment operating margin contracted from 25.8% to 23.4%. This is a significant headwind given Health's outsized historical contribution to Leidos' total operating income.
M&A and Restructuring Costs Dragging the Bottom Line
Management framed Q2 as another strong quarter, but the specific data contradicts the purely bullish narrative: GAAP Net Income actually fell 9% YoY (from $393M to $356M). The culprit was $29M in costs associated with the Entrust acquisition, the Analogic JV, and the NorthStar 2030 restructuring. While management excludes these to show 2% Non-GAAP EPS growth, these are real cash costs reflecting the friction of aggressive portfolio shaping.
Transitioning to Defense Hardware Production
Leidos continues to successfully evolve from a pure IT services provider to a defense technology and hardware manufacturer. Key Q2 awards highlight this transition: an $88M contract for the MACH-TB 2.0 experimental hypersonic glide vehicles, and a $350M modification for advanced low-band surveillance radar infrastructure. This aligns with broader macro defense spending shifts toward agile, multi-domain intelligence and electronic warfare (EW).
Elite Cash Conversion Enabling Rapid De-leveraging
The company's cash generation is accelerating. Q2 operating cash flow was a staggering $793M, representing a 224% conversion ratio on net income. This allowed Leidos to immediately pay down $300M in commercial paper tied to the Entrust acquisition while still returning $127M to shareholders via buybacks and dividends.
Tough Margin Comparables
Total Adjusted EBITDA margin decelerated to 13.8% from 15.2% a year ago. While Q2 2025 was artificially inflated by a $25M insurance reimbursement, the drop still reflects underlying normalization in spending and the margin drag from integrating new, lower-margin development contracts in the Defense tech space.
Other KPIs
Stable. The largest segment grew 6.5% YoY, maintaining steady non-GAAP operating margins at 10.1%. This reflects consistent Intelligence Community mission support demand and the integration of Kudu Dynamics.
Accelerating. Backlog grew 5% YoY, with funded backlog surging 44% YoY to $10.2 billion. The trailing-twelve-month book-to-bill ratio remained healthy at 1.1x, providing high visibility for FY27.
Guidance
Accelerating. Raised from prior guidance of $18.00B-$18.40B. The midpoint implies ~6.5% YoY growth over FY25's $17.2B, driven heavily by the Entrust integration and Homeland demand.
Stable. Maintained at prior levels. This represents a deceleration from the 14.1% delivered in FY25, validating that the record margins seen last year were peak levels and that the company is absorbing investment/M&A friction.
Accelerating slightly. The floor was raised by $0.10. At the midpoint ($12.35), this implies ~3% YoY growth over FY25's $11.99, reflecting share repurchases and top-line expansion offsetting margin compression.
Accelerating. Raised by $50M from prior guidance of ~$1.80B. This implies growth over FY25's massive $1.75B and signals deep confidence in working capital management and prompt government collections.
Key Questions
Health Segment Trajectory
With Health revenues down 8% and margins contracting, what is the new normalized baseline for this segment now that the medical disability exam backlog has eased?
Margin Profiles of New M&A
Homeland margins improved significantly this quarter with Entrust integrated. Is a 12%+ Non-GAAP operating margin the new structural normal for this segment, or were there favorable one-time task orders?
Analogic JV Economics
How will the pending joint venture with Analogic Corporation impact top-line revenue recognition and bottom-line margins for the CBP Medium Energy Mobile Systems once finalized?